Sumoylation Inhibits the Growth Suppressive Properties of Ikaros.

Date publication

janvier 2016

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CHAN Susan , Dr KASTNER Philippe , Pr MAUVIEUX Laurent , Dr KIRSTETTER Peggy

Tous les auteurs :
Apostolov A, Litim-Mecheri I, Oravecz A, Goepp M, Kirstetter P, Marchal P, Ittel A, Mauvieux L, Chan S, Kastner P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27315244

Résumé

The Ikaros transcription factor is a tumor suppressor that is also important for lymphocyte development. How post-translational modifications influence Ikaros function remains partially understood. We show that Ikaros undergoes sumoylation in developing T cells that correspond to mono-, bi- or poly-sumoylation by SUMO1 and/or SUMO2/3 on three lysine residues (K58, K240 and K425). Sumoylation occurs in the nucleus and requires DNA binding by Ikaros. Sumoylated Ikaros is less effective than unsumoylated forms at inhibiting the expansion of murine leukemic cells, and Ikaros sumoylation is abundant in human B-cell acute lymphoblastic leukemic cells, but not in healthy peripheral blood leukocytes. Our results suggest that sumoylation may be important in modulating the tumor suppressor function of Ikaros.

Référence

PLoS ONE. 2016 ;11(6):e0157767